Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV001377786 | SCV001575209 | likely pathogenic | Autosomal recessive limb-girdle muscular dystrophy type 2D | 2020-07-21 | criteria provided, single submitter | clinical testing | Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site, but this prediction has not been confirmed by published transcriptional studies. This variant has been observed in individual(s) with autosomal recessive muscular dystrophy (PMID: 7663524). This variant is also referred to as AG>AT (-1 exon 8) in the literature. This variant is not present in population databases (ExAC no frequency). This sequence change affects an acceptor splice site in intron 7 of the SGCA gene. It is expected to disrupt RNA splicing and likely results in an absent or disrupted protein product. Donor and acceptor splice site variants typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in SGCA are known to be pathogenic (PMID: 9192266). In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. |
Baylor Genetics | RCV001377786 | SCV004203169 | pathogenic | Autosomal recessive limb-girdle muscular dystrophy type 2D | 2023-07-26 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001377786 | SCV002087585 | likely pathogenic | Autosomal recessive limb-girdle muscular dystrophy type 2D | 2020-06-15 | no assertion criteria provided | clinical testing |